Product Information
DOXEPIN HCL 3 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $1.3334 per EA under NDC 00228331503. Its NADAC has been published 337 times since Apr 22, 2020.
FDA first approved this application on Jul 26, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228331503
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXEPIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA201951FDA Approved
7/26/2013
TE Code
AB
On Market Since
1/2/2020
Pharmacological Classes
Price Statistics
The NADAC for DOXEPIN HCL 3 MG TABLET has been published 337 times since Apr 22, 2020, and over the history we have for it it has declined 86.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3334 per EA |
|---|---|
| All-time high | $10.8829 (Oct 14, 2020) |
| All-time low | $1.3271 (Jul 22, 2026) |
| 52-week high | $2.1099 |
| 52-week low | $1.3271 |
| Median price | $6.9615 |
| Average price | $5.9778 |
| Largest weekly change | -32.6% (Sep 20, 2023) |
| Weeks tracked | 337 |
| Tracking since | Apr 22, 2020 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Doxepin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXEPIN HCL 3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DOXEPIN HCL 3 MG TABLET, manufactured by Actavis Pharma, Inc., is $1.3334 per EA (NDC 00228331503), effective Sep 30, 2026.
How has the price of DOXEPIN HCL 3 MG TABLET changed over time?
Over the history we have for it, the NADAC for DOXEPIN HCL 3 MG TABLET has declined 86.9%. It has been tracked across 337 weekly CMS publications since Apr 22, 2020.
What are the highest and lowest recorded NADAC prices for DOXEPIN HCL 3 MG TABLET?
Since Apr 22, 2020, the NADAC for DOXEPIN HCL 3 MG TABLET has ranged from a low of $1.3271 (Jul 22, 2026) to a high of $10.8829 (Oct 14, 2020), with a median of $6.9615 per EA.
Are there cheaper alternatives to DOXEPIN HCL 3 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DOXEPIN HCL 3 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures DOXEPIN HCL 3 MG TABLET?
DOXEPIN HCL 3 MG TABLET (NDC 00228331503) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.